Oryzon onboards first patient in Phase IIb borderline personality disorder study,

Oryzon Genomics has enrolled the first patient in PORTICO, a Phase IIb clinical trial assessing vafidemstat as a treatment for borderline personality …, Oryzon Genomics has enrolled the first patient in PORTICO, a Phase IIb clinical trial assessing vafidemstat as a treatment for borderline personality …, Read More

Scroll to Top